Crispr Therapeutics Financials
| CRSP Stock | USD 55.65 0.76 1.35% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.23 | 17.5389 |
|
|
The financial analysis of Crispr Therapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Crispr Therapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize Crispr Therapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Crispr Therapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Crispr Therapeutics.
Net Income |
|
With this module, you can analyze Crispr financials for your investing period. You should be able to track the changes in Crispr Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Crispr | Select Account or Indicator |
Understanding current and past Crispr Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Crispr Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Crispr Therapeutics' assets may result in an increase in income on the income statement.
The data published in Crispr Therapeutics' official financial statements usually reflect Crispr Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Crispr Therapeutics. For example, before you start analyzing numbers published by Crispr accountants, it's critical to develop an understanding of what Crispr Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Crispr Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Crispr Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Crispr Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Crispr Therapeutics AG. Please utilize our Beneish M Score to check the likelihood of Crispr Therapeutics' management manipulating its earnings.
Crispr Therapeutics Stock Summary
Crispr Therapeutics competes with Beam TherapeuticsInc, Editas Medicine, Caribou Biosciences, Verve Therapeutics, and Intellia Therapeutics. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | CH0334081137 |
| CUSIP | H17182108 |
| Location | Switzerland |
| Business Address | Baarerstrasse 14, Zug, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.crisprtx.com |
| Phone | 41 41 561 32 77 |
| Currency | USD - US Dollar |
You should never invest in Crispr Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Crispr Stock, because this is throwing your money away. Analyzing the key information contained in Crispr Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Crispr Therapeutics Key Financial Ratios
Generally speaking, Crispr Therapeutics' financial ratios allow both analysts and investors to convert raw data from Crispr Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Crispr Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Crispr Therapeutics reports annually and quarterly.| Return On Equity | -0.0817 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | 0.35 % |
Crispr Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.1B | 1.8B | 2.8B | 2.2B | 2.2B | 1.3B | |
| Other Current Liab | 41.7M | 71.5M | 91.9M | 65.5M | 50.9M | 36.6M | |
| Other Liab | 26.2M | 19.4M | 19.7M | 18.3M | 16.5M | 15.6M | |
| Net Tangible Assets | 939.2M | 1.7B | 2.4B | 1.9B | 2.2B | 2.3B | |
| Net Debt | (891.2M) | (1.1B) | (698.0M) | 32.1M | (150.8M) | (158.4M) | |
| Retained Earnings | (224.7M) | (573.6M) | (195.9M) | (846.1M) | (999.7M) | (949.7M) | |
| Accounts Payable | 5.9M | 9.1M | 14.8M | 27.4M | 38.1M | 40.1M | |
| Cash | 943.8M | 1.2B | 923.0M | 211.9M | 389.5M | 528.6M | |
| Other Assets | 6.1M | 18.1M | 22.2M | 16.3M | 18.7M | 19.7M | |
| Net Receivables | 99K | 144K | 305K | 11.2M | 200M | 210M | |
| Other Current Assets | 43.7M | 26.1M | 38.1M | 37.7M | 14.4M | 19.5M | |
| Total Liab | 127.3M | 163.7M | 352.4M | 367.6M | 346.8M | 203.2M | |
| Total Current Assets | 987.5M | 1.7B | 2.4B | 1.9B | 1.9B | 1.1B | |
| Short Term Debt | 8.5M | 11.4M | 12.2M | 15.8M | 15.6M | 16.4M | |
| Intangible Assets | 235K | 180K | 125K | 71K | 16K | 15.2K | |
| Common Stock | 1.8M | 2.3M | 2.4M | 2.4M | 2.5M | 1.7M | |
| Capital Surpluse | 1.2B | 2.2B | 2.6B | 2.7B | 3.1B | 3.3B | |
| Net Invested Capital | 939.4M | 1.7B | 2.4B | 1.9B | 1.9B | 1.5B |
Crispr Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Crispr Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 25.3M | 6.4M | 24.0M | 46.8M | 53.9M | 56.6M | |
| Total Revenue | 289.6M | 543K | 913.1M | 436K | 370M | 388.5M | |
| Gross Profit | 289.6M | (268.9M) | 913.1M | (109.8M) | 239.8M | 122.3M | |
| Operating Income | 46.7M | (354.4M) | 373.5M | (673.2M) | (222.5M) | (211.4M) | |
| Ebit | 46.7M | (354.4M) | 373.5M | (673.2M) | (222.5M) | (211.4M) | |
| Research Development | 179.4M | 266.9M | 438.6M | 461.6M | 387.3M | 217.1M | |
| Ebitda | 51.5M | (345.3M) | 391.5M | (649.0M) | (202.7M) | (192.6M) | |
| Cost Of Revenue | 179.4M | 269.4M | 101.2M | 110.3M | 130.3M | 113.9M | |
| Income Before Tax | 67.3M | (348.1M) | 379.5M | (650.5M) | (150.7M) | (158.3M) | |
| Net Income | 66.9M | (348.9M) | 377.7M | (650.2M) | (153.6M) | (161.3M) | |
| Income Tax Expense | 448K | 809K | 1.9M | (325K) | 2.9M | 3.0M | |
| Tax Provision | 448K | 809K | 1.9M | (325K) | 2.9M | 3.0M |
Crispr Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Crispr Therapeutics. It measures of how well Crispr is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Crispr Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Crispr had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Crispr Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 1.3M | (522.8M) | (953.7M) | (258.7M) | 280.6M | 294.6M | |
| Change In Cash | 489M | 236.7M | (245.5M) | (715.9M) | 177.0M | 185.9M | |
| Free Cash Flow | 50.0M | (256.7M) | 457.3M | (532.9M) | (272.3M) | (258.7M) | |
| Depreciation | 4.7M | 9.2M | 18.0M | 24.2M | 19.8M | 20.8M | |
| Other Non Cash Items | (10.5M) | 1.9M | 14.1M | 12.5M | (14.0M) | (13.3M) | |
| Capital Expenditures | 6.7M | 18.4M | 81.7M | 37.2M | 12.0M | 18.9M | |
| Net Income | 66.9M | (348.9M) | 377.7M | (650.2M) | (153.6M) | (161.3M) | |
| End Period Cash Flow | 948.8M | 1.2B | 939.9M | 224.1M | 401.1M | 535.8M | |
| Change To Netincome | 49.5M | 67.9M | 102.4M | 110.4M | 127.0M | 133.3M | |
| Change To Inventory | (5.0M) | (25.7M) | (37.5M) | 23.3M | 26.8M | 28.2M | |
| Change Receivables | (11K) | (45K) | (161K) | 305K | 350.8K | 368.3K |
Crispr Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Crispr Therapeutics's current stock value. Our valuation model uses many indicators to compare Crispr Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Crispr Therapeutics competition to find correlations between indicators driving Crispr Therapeutics's intrinsic value. More Info.Crispr Therapeutics AG is rated fifth in return on equity category among related companies. It is rated fourth in return on asset category among related companies . At this time, Crispr Therapeutics' Return On Equity is relatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Crispr Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Crispr Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Crispr Therapeutics' earnings, one of the primary drivers of an investment's value.Crispr Therapeutics Systematic Risk
Crispr Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Crispr Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Crispr Therapeutics correlated with the market. If Beta is less than 0 Crispr Therapeutics generally moves in the opposite direction as compared to the market. If Crispr Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Crispr Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Crispr Therapeutics is generally in the same direction as the market. If Beta > 1 Crispr Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Crispr Therapeutics Financials
What exactly are Crispr Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Crispr Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Crispr Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Crispr Therapeutics investors may use each financial statement separately, they are all related. The changes in Crispr Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Crispr Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Crispr Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Crispr Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Crispr has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Crispr Therapeutics' financials are consistent with your investment objective using the following steps:- Review Crispr Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Crispr Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Crispr Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Crispr Therapeutics' stock is overvalued or undervalued.
Today, most investors in Crispr Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Crispr Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Crispr Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Crispr Therapeutics April 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Crispr Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Crispr Therapeutics AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Crispr Therapeutics AG based on widely used predictive technical indicators. In general, we focus on analyzing Crispr Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Crispr Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 14.48 | |||
| Value At Risk | (4.62) | |||
| Potential Upside | 6.88 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 4.686 | Quarterly Revenue Growth 33.5 K | Return On Assets (0.06) | Return On Equity (0.08) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.